TIDMDDDD
4d Pharma PLC
17 May 2021
4D pharma to Present Additional Data from Phase II Study of
Blautix for the Treatment of Irritable Bowel Syndrome at Digestive
Disease Week (DDW) 2021
Company will host conference call on Tuesday, May 25, 2021 at
12:00 p.m. EDT
Leeds, UK, May 17, 2021 , - 4D pharma plc (AIM: DDDD, NASDAQ:
LBPS), a pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs) - a novel class of drug derived from
the microbiome, today announced that it will present data from its
Phase II study of single strain LBP Blautix(R) in patients with
irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D in a poster
session at Digestive Disease Week (DDW) 2021, taking place
virtually May 21-23, 2021.
Details of the poster presentation are as follows:
Presentation Title : A Phase II Study of Live Biotherapeutic
Blautix in Irritable Bowel Syndrome (IBS) Patients with Subtypes
IBS-C and IBS-D.
Session Date & Time : Saturday, May 22, 2021 from 12:15pm to
1:00pm EDT (5:15pm to 6:00pm BST)
Session Title : Microbial-Based Therapy
Presenter : Eamonn Quigley, M.D. Chief, Division of
Gastroenterology and Hepatology at Houston Methodist
Abstract Number : 3525656
4D pharma will host a virtual event to review the additional
data presented at DDW 2021 and how this relates to the current IBS
treatment landscape. The event will take place on Tuesday, May 25,
2021 at 5:00pm BST (12:00pm EDT). The event will feature a
presentation from 4D pharma management followed by an analyst
Q&A session.
A live webcast of the event will be available via the Events
section of the 4D pharma website at www.4dpharmaplc.com. To access
the call, please dial +1-760-294-1674 (United States) or
+44-203-059-58-69 (United Kingdom) and reference Conference ID
20210360. A replay of the webcast will be available following the
event.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx(R), that rationally identifies Live Biotherapeutics based
on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in
patients hospitalized with COVID-19, and Blautix(R) in Irritable
Bowel Syndrome (IBS) which has completed a successful Phase II
trial. Preclinical-stage programs include candidates for CNS
disease such as Parkinson's disease and other neurodegenerative
conditions. The Company has a research collaboration with MSD, a
tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to
discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
Contact Information:
4D pharma
Investor Relations: ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496
3000
Philip Davies / Iqra Amin / James Fischer (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson / Phil Walker
Stern Investor Relations, Inc. +1-212-362-1200
Julie Seidel Julie.seidel@sternir.com
Image Box Communications +44 (0)20 8943 4685
Neil Hunter / Michelle Boxall
neil@ibcomms.agency / michelle@ibcomms.agency
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADKABNOBKDCPD
(END) Dow Jones Newswires
May 17, 2021 02:00 ET (06:00 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024